Clinical trials in prostatic cancer - Interpretations and misinterpretations

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 3, 1999, Pages 120-125

  Newling, D W W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Interpretation

Indexed keywords

ESTRAMUSTINE PHOSPHATE; KI 67 ANTIGEN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER STAGING; FOLLOW UP; HORMONE INHIBITION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TESTOSTERONE SYNTHESIS; TREATMENT PLANNING;

EID: 0032878789     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500304     Document Type: Review

References (18)

1. Vanchieri LP. Annual percentage change in cancer incidence rates 1973-1990 vs 1990-1995. J Nat Cancer Inst, 1998; 90: 419.
2. Wang KW et al. Prostatic antigen: a new potential marker for prostatic cancer. Prostate 1998; 2: 89-96.
3. Eisenberger MA, Nelson WG. How much can we rely on the level of PSA as an endpoint for evaluation of clinical trials? A word of caution. J Nat Cancer Inst. 1996; 88: 779-781.
4. Calais da Silva F. Screening for early prostate cancer - is it possible or justifiable? In: Peeling W. B. (ed), Questions and Uncertainties About Prostate Cancer. Blackwell Science: Oxford, 1996; pp 283-304.
5. Tyrrell, D et al. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Eur. Urol, 1998; 33: 39-53.
6. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? BMJ 1998; 7155: 362-363.
7. Zelen M, A new design for randomized clinical trials. NEJM 1979; 300: 1242-1245.
8. Newling D et al. Assessment of hormone refractory prostate cancer. Urology 1997; 49 (suppl 4A) 46-53.
9. EORTC - A practical guide to EORTC studies. In: Therasse P. (ed), Trial methodology. EORTC Publications: Brussels, 1996, 57-89.
10. Schröder FH et al. Phase II studies on prostate cancer. Urology 1997; 49: (suppl. 4A): 3-14.
11. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs deferred treatment for advanced prostatic cancer: initial results of the MRC trial. BJU 1997; 79: 235-246.
12. Iversen P. Endocrine therapy: goals and limitations. In: Schrödet FH (ed), Recent advances in prostate cancer and BPH, Proceedings of the IVth Congress on Progess and Controversies in Oncological Urology, Rotterdam. April 11-13, 1996, Parthenon, 147-155.
13. Qayan A, Scaletsky R, Waxman J. Autocrine stimulation by gonadotrophin-releasing hormone-like factors of human hormon-responsive prostate cancer cells in culture. In: Newling DWW, with Jones WG, (ed). Prostate cancer and testicular Cancer. Wiley-Liss: New York, 1990; pp 121-128.
14. Schröder FH, Whelan P, Kurth KH and members of the EORTC GU-Group Metastatic prostate cancer and anti-androgen monotherapy (flutamide vs cyproterone acetate) - side-effects and sexual function. Eur. Urol. 1996; 2: 256 abstract 996.
15. Prostate Cancer Triallists Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 1995; 265-269.
16. Peto R The latest update on the PCTCG analysis of 8000 patients randomised to castration or MAB′ - presented at PACIOU V, October 16-17, 1998, Rotterdam.
17. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J. Clin. Oncol. 1996; 14: 1756-1764.
18. Wilding G, quoted in Eisenberger MA and Nelson WH. How much can we rely on PSA as an endpoint for evaluation of clinical trials - a word of caution? J. Nat. Cancer Inst. 1996; 88: 779-781.